<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126758</url>
  </required_header>
  <id_info>
    <org_study_id>CAP-1002-DMD-04</org_study_id>
    <nct_id>NCT05126758</nct_id>
  </id_info>
  <brief_title>A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)</brief_title>
  <acronym>HOPE-3</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capricor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capricor Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HOPE-3 is a multi-center, randomized, double-blind, placebo-controlled clinical trial&#xD;
      evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants&#xD;
      with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who&#xD;
      meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo&#xD;
      every 3 months for a total of 4 doses during a 12-month period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upto 68 eligible study participants will be randomized to either CAP-1002 or placebo in a 1:1&#xD;
      ratio.&#xD;
&#xD;
        -  The trial will include visits at Screening, Baseline/Day 1, Week 4, and Months 3, 6, 9,&#xD;
           and 12 with IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9.&#xD;
&#xD;
        -  Safety evaluations will include adverse events, concomitant medications, physical exam,&#xD;
           vital signs, 12-lead ECG, and clinical laboratory testing.&#xD;
&#xD;
        -  Efficacy will be evaluated in the Performance of the Upper Limb, Egen Klassifikation&#xD;
           Scale, North Star Ambulatory Assessment (ambulatory subjects only), 10 meter walk test&#xD;
           (ambulatory subjects only), cardiac MRI, blood collection and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate full upper limb function at Month 12 following 4 IV administrations of CAP-1002</measure>
    <time_frame>At Month 12</time_frame>
    <description>Mean change from baseline in full PUL 2.0 at Month 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate cardiac muscle function and structure at Month 12 following 4 IV administrations of CAP-1002</measure>
    <time_frame>At Month 12</time_frame>
    <description>Mean change from baseline in ejection fraction at Month 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Muscular Dystrophies</condition>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <condition>Muscular Disorders, Atrophic</condition>
  <condition>Muscular Diseases</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>CAP-1002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAP-1002</intervention_name>
    <description>The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.&#xD;
Other Names:&#xD;
Cardiosphere-Derived Cells&#xD;
CDCs</description>
    <arm_group_label>CAP-1002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects at least 10 years of age at time of consent who are willing and able to&#xD;
             provide informed consent to participate in the trial and diagnosed with DMD as&#xD;
             confirmed by the Investigator&#xD;
&#xD;
          2. Genetically confirmed DMD&#xD;
&#xD;
          3. Reduced ability to walk/run (if ambulatory)&#xD;
&#xD;
          4. Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at&#xD;
             least 6 months prior to study participation, except for weight-based or&#xD;
             toxicity-related adjustments&#xD;
&#xD;
          5. Current and up-to-date immunizations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Left ventricular ejection fraction (LVEF) &lt; 35%&#xD;
&#xD;
          2. Elbow-flexion contractures &gt; 30Â° in both extremities&#xD;
&#xD;
          3. Body mass index (BMI) &gt; 45&#xD;
&#xD;
          4. Percent predicted forced vital capacity (FVC%) &lt; 35%&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig McDonald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Stiegler</last_name>
    <phone>310.358.3046</phone>
    <email>pstiegler@capricor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veena Ramanna</last_name>
    <phone>310.358.3046</phone>
    <email>vramanna@capricor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Colleen Anthonisen</last_name>
      <phone>916-734-4307</phone>
      <email>canthonisen@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Performance of the Upper Limb</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Non-Ambulatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Muscular Disorders, Atrophic</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

